Abstract

The hypoglycemic effect of glibornuride (Glutril), a new derivate of the hypoglycemic sulfonylureas, was studied on 97 diabetics registered at the Diabetic Clinic of Seoul National University Hospital. From the observation of the effect after administering for 1-19 months, average 4. 8 months, to the almost not or poorly controlIed maturity-onset diabetic patients, the following results were obtained. Glibornuride was given to 62 cases who had been treated with dietery regimen alone and the excellent or good control was obtained in 37 cases (60%). 2.Out of 30 csses who had been treated with other sulfonylurea derivates, 12 cases (40%) showed excellent or good control. 3. Glibornuride treatment in 5 cases who had been treated with less than 20 units of NPH insulin, resulted in excellent or good control in 3 cases (60%), 4. The influenoe of age, body weight, and duration of disease was studied. According to the resuits, difference of age showed no remarkable influence on the effect of glibornuride, but relatively better results were obtained in the group of obese patients, namely 80% of them showed excellent or good control. The shorter the duration of disease, the better the results. 5. The required period to show excellent or good control was 1-20 weeks, average 3-7 weeks, and the higher the fasting blood suger,level Before glibornuride administration, the longer the required period. At least 4-8 weeks siem to be necessary to extimate the effect of this agent, 6. During this trial there were 5 cases (5%) of primary failure and 3 cases (3%) of relative secondary failure among the relatively severe paticnts with long diabetic duration. 7. As the side effects, hypoglycemic symptoms, epigastric discomfort, nausea, fstigability or indigestion, all transient and mild, were see respectivefy in 7 cases (7. 2%), but there was no case who had to disconiinue this agent. Connsidering strong hypoglycemic effect and absence of any remarkable side effects and toxidity during the clinic studies, we can conclude that glibornuride is thought to be an useful agent in long term therapy of diabetes in the suitable indication.